Cost-effectiveness analysis of aprepitant in Japanese patients who received high-dose cisplatin.

e18924Background: Chemotherapy-induced nausea and vomiting (CINV) remains a major adverse event in cancer chemotherapy. Aprepitant, in combination with a serotonin receptor antagonist and dexamethasone, is effective in preventing CINV. The objective of this study was to define, from the perspective of the Japanese National Health Insurance system, the cost-effectiveness of aprepitant for patients receiving high-dose cisplatin. Methods: We developed a decision analytic model based on the results of a phase II randomized clinical trial comparing aprepitant containing three-drug regimen versus non-aprepitant two drug regimen on Japanese patients who received cisplatin-containing highly emetogenic chemotherapy. Resource use data were based on the randomized clinical trial and routine clinical practice. Incremental cost effectiveness ratio (ICER) was calculated both in the outpatient care setting (OCS) and in the inpatient care setting (ICS). Deterministic and probabilistic sensitivity analysis addressed uncer...